These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 37332488

  • 1. Neurocognitive testing in a murine model of mucopolysaccharidosis type IIIA.
    Pericleous K, McIntyre C, Fuller M.
    Mol Genet Metab Rep; 2023 Sep; 36():100985. PubMed ID: 37332488
    [Abstract] [Full Text] [Related]

  • 2. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
    Gustavsson S, Ohlin Sjöström E, Tjernberg A, Janson J, Westermark U, Andersson T, Makower Å, Arnelöf E, Andersson G, Svartengren J, Ekholm C, Svensson Gelius S.
    Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA).
    Hemsley KM, Hopwood JJ.
    Behav Brain Res; 2005 Mar 30; 158(2):191-9. PubMed ID: 15698885
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Retinal Degeneration in MPS-IIIA Mouse Model.
    Intartaglia D, Giamundo G, Marrocco E, Maffia V, Salierno FG, Nusco E, Fraldi A, Conte I, Sorrentino NC.
    Front Cell Dev Biol; 2020 Mar 30; 8():132. PubMed ID: 32195255
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Glycosaminoglycan levels and structure in a mucopolysaccharidosis IIIA mice and the effect of a highly secreted sulfamidase engineered to cross the blood-brain barrier.
    Maccari F, Sorrentino NC, Mantovani V, Galeotti F, Fraldi A, Volpi N.
    Metab Brain Dis; 2017 Feb 30; 32(1):203-210. PubMed ID: 27585464
    [Abstract] [Full Text] [Related]

  • 13. MPS-IIIA mice acquire autistic behaviours with age.
    Lau AA, Tamang SJ, Hemsley KM.
    J Inherit Metab Dis; 2018 Jul 30; 41(4):669-677. PubMed ID: 29520737
    [Abstract] [Full Text] [Related]

  • 14. An Engineered sgsh Mutant Zebrafish Recapitulates Molecular and Behavioural Pathobiology of Sanfilippo Syndrome A/MPS IIIA.
    Douek AM, Amiri Khabooshan M, Henry J, Stamatis SA, Kreuder F, Ramm G, Änkö ML, Wlodkowic D, Kaslin J.
    Int J Mol Sci; 2021 May 31; 22(11):. PubMed ID: 34073041
    [Abstract] [Full Text] [Related]

  • 15. Impaired neural differentiation of MPS IIIA patient induced pluripotent stem cell-derived neural progenitor cells.
    Lehmann RJ, Jolly LA, Johnson BV, Lord MS, Kim HN, Saville JT, Fuller M, Byers S, Derrick-Roberts ALK.
    Mol Genet Metab Rep; 2021 Dec 31; 29():100811. PubMed ID: 34712574
    [Abstract] [Full Text] [Related]

  • 16. Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.
    Langford-Smith A, Wilkinson FL, Langford-Smith KJ, Holley RJ, Sergijenko A, Howe SJ, Bennett WR, Jones SA, Wraith J, Merry CL, Wynn RF, Bigger BW.
    Mol Ther; 2012 Aug 31; 20(8):1610-21. PubMed ID: 22547151
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.